BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LMY-922 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LMY-922\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07679919-3372@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:LMY-922: Phase 1 readout est. (NCT07679919)
DESCRIPTION:LMY-922\, phase 1\, Multiple Myeloma.\nStudy: BAFF CAR-T Cells 
 (LMY-922) for Treatment of Refractory Hematologic Malignancies\nEstimated 
 primary completion: April 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/lmy-922#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07679919
URL:https://assetmemo.bio/drug/lmy-922#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729995-3372@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:LMY-922: Phase 1 readout est. (NCT07729995)
DESCRIPTION:LMY-922\, phase 1.\nStudy: BAFF CAR-T Cells (LMY-922) for Treat
 ment of Refractory Autoimmune Disease\nEstimated primary completion: March
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/lmy-922#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07729995
URL:https://assetmemo.bio/drug/lmy-922#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
